A first-in-human phase I study of the ATP-competitive AKT inhibitor Ipatasertib demonstrates Robust and safe targeting of AKT in patients with solid tumors

  1. Saura, C.
  2. Roda, D.
  3. Roselló, S.
  4. Oliveira, M.
  5. Macarulla, T.
  6. Pérez-Fidalgo, J.A.
  7. Morales-Barrera, R.
  8. Sanchis-García, J.M.
  9. Musib, L.
  10. Budha, N.
  11. Zhu, J.
  12. Nannini, M.
  13. Chan, W.Y.
  14. Sanabria Bohórquez, S.M.
  15. Meng, R.D.
  16. Lin, K.
  17. Yan, Y.
  18. Patel, P.
  19. Baselga, J.
  20. Tabernero, J.
  21. Cervantes, A.
Revue:
Cancer Discovery

ISSN: 2159-8290,  2159-8274

Année de publication: 2017

Volumen: 7

Número: 1

Pages: 102-113

Type: Article

DOI: 10.1158/2159-8290.CD-16-0512 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus